Increasing Knowledge About Alpha-1 Antitrypsin Deficiency in the Chronic Obstructive Pulmonary Disease Population by Barta, Maureen Ann Wentink
Walden University
ScholarWorks
Walden Dissertations and Doctoral Studies Walden Dissertations and Doctoral StudiesCollection
2015
Increasing Knowledge About Alpha-1 Antitrypsin
Deficiency in the Chronic Obstructive Pulmonary
Disease Population
Maureen Ann Wentink Barta
Walden University
Follow this and additional works at: https://scholarworks.waldenu.edu/dissertations
Part of the Epidemiology Commons, Genetics Commons, and the Health and Medical
Administration Commons
This Dissertation is brought to you for free and open access by the Walden Dissertations and Doctoral Studies Collection at ScholarWorks. It has been
accepted for inclusion in Walden Dissertations and Doctoral Studies by an authorized administrator of ScholarWorks. For more information, please
contact ScholarWorks@waldenu.edu.
  
 
Walden University 
 
 
 
College of Health Sciences 
 
 
 
 
This is to certify that the doctoral study by 
 
 
Maureen Barta 
 
 
has been found to be complete and satisfactory in all respects,  
and that any and all revisions required by  
the review committee have been made. 
 
 
Review Committee 
Dr. Cheryl Holly, Committee Chairperson, Health Services Faculty 
Dr. Eric Anderson, Committee Member, Health Services Faculty 
Dr. Vincent Hall, University Reviewer, Health Services Faculty 
 
 
 
 
 
Chief Academic Officer 
Eric Riedel, Ph.D. 
 
 
 
Walden University 
2015 
 
 
 
 
 
 
  
 
Abstract 
Increasing Knowledge About AATD in the COPD Population 
 
by 
Maureen Ann Wentink Barta 
 
MSN, Pacific Lutheran University, 1996 
BSN, Pacific Lutheran University, 1992 
 
 
Project Submitted in Fulfillment 
Of the Requirements for the Degree of 
Doctor of Nursing Practice 
 
 
Walden University 
November 2015 
  
  
 
Abstract 
The purpose of the project was to increase awareness about alpha-1 antitrypsin deficiency 
(AATD) in chronic obstructive pulmonary disease (COPD), particularly among those with a 
familial history of genetic factor AATD; an additional goal was to understand its relationship to 
COPD.  COPD is the third leading cause of death in the United States, with more than half of 
COPD patients experiencing significant disabilities.  Major causes for COPD include smoking, 
air pollution, secondary smoke, upper respiratory infections, hereditary factors, occupational 
factors, environmental factors, and socioeconomic factors.  Genetic factors, however, also play a 
significant role in early onset COPD and in those who smoke and have the genetic factor related 
to COPD (AATD), symptoms are more severe and exacerbations more frequent.  Undiagnosed 
AATD can result in under treatment and lack of planning for preventing COPD onset and 
exacerbation in these patients.  COPD clients of a local pharmacy (n = 31) were invited to 
complete a Likert survey and given materials on COPD exacerbation prevention and information 
on AATD.   Results indicated that 38.7% of respondents had early onset symptoms, positive 
family history, and no improvement in symptoms with smoking cessation.  The results support 
that targeting those family members with COPD and providing information on genetic factors for 
this condition could decrease the frequency and severity of exacerbations. This is in keeping with 
the health belief model that guided this study in that a perceived risk for harm has the potential to 
improve the use of preventative health measures in individuals. 
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Section 1: Nature of the Project 
 Increasing Knowledge About AATD in the COPD Population  
The overall aim of this project was to increase knowledge and awareness 
regarding the genetic factor alpha -1 antitrypsin deficiency (AATD) and its relationship 
to increased severity of symptoms and more frequent exacerbations in those with 
chronic obstructive pulmonary disease (COPD), particularly among those with a familial 
history of COPD. COPD is a chronic disease targeted by Healthy People 2020 as it is the 
third leading cause of death in the United States (CDC, 2013). More than half of COPD 
patients have limitations in employment, family life, social life, and ability to engage in 
household chores (American Lung Association, 2011).  Major causes for COPD include 
smoking, air pollution, secondary smoke, upper respiratory infections, hereditary factors, 
occupational factors, environmental factors, and socioeconomic factors (American Lung 
Association, 2011).  Genetic factors also play a significant role in early onset COPD and 
in those who smoke with the genetic factors related to COPD (i.e., AATD), symptoms 
are more severe and exacerbations more frequent (Alpha-1 Foundation, 2013).  
Undiagnosed AATD can result in under-treatment and lack of planning for preventing 
COPD onset and exacerbation in these patients.  Notably, almost 90% of COPD deaths 
are related to smoking habits, which is a preventable factor in COPD onset and 
exacerbation (CDC, 2012).  Although smoking rates in adults have decreased from over 
40% in the 1950s to just above 19% currently with cessation efforts, those who have a 
genetic predisposition such as AATD and who smoke continue to have a higher 
mortality rate. 
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ATTD is a genetic disease that causes the body to not have the necessary lung 
protection to fight inflammation and irritants.  This results in the early onset of COPD in 
afflicted individuals (American Thoracic Association, 2003).  In 2003, the American 
Thoracic Association set a standard for genetic testing in adult onset asthma and newly 
diagnosed COPD clients for AATD.  Identifying the presence of AATD within the 
COPD population allows for preventive health program development for the most 
effective interventions and teaching strategies for COPD prevention.  The COPD 
population may be unaware of AATD as an influencing factor on the exacerbation and 
severity of this disease condition, resulting in under-treatment and lack of preventive 
planning. 
 
Overview of Evidence-based Project   
 The purpose of the project was to increase knowledge and awareness regarding 
the genetic factor AATD in those patients diagnosed with COPD and to provide 
opportunities for genetic testing and information on self-care management strategies.  
The overall aim of this project was to improve quality of life and decrease exacerbations 
and severity of symptoms in the COPD population by increasing awareness of AATD 
within a sample of that population and providing access to strategies for preventing 
exacerbation for high risk individuals.  The theoretical basis was the health belief model 
that asserts motivation to participate in health promotion practices is related to perceived 
susceptibility to a specific disease (Hodges & Videto, 2011). 
There were both long term and short term goals for this increasing knowledge 
about AATD in the COPD population.  The long term goals were, first, decreasing 
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exacerbation rates within the COPD population, and, secondly, improving the quality of 
life for those afflicted with COPD through the use of self-care management techniques.  
Short term goals for this project were increased awareness of potential genetic 
predisposition for COPD and increased understanding of strategies to minimize risk for 
COPD exacerbation within the sample population.  Therefore, the specific objectives of 
the project were to (a) provide resources for AATD risk, testing, and diagnosis along 
with self-care management techniques for prevention of COPD exacerbation, and (b) 
survey residents who are diagnosed with COPD in a defined geographical area regarding 
AATD risk factors.     
Significance and Relevance to Practice 
The significance and relevance to practice for this project was related to a 
potential improvement in the frequency and severity of COPD symptom exacerbation 
for those who are at risk for genetic predisposition to COPD from AATD (CDC, 2013).  
Awareness of risk potential, according to the health belief model, provides for an 
increase in health promotion behaviors.  Among the strategies that can reduce the risk of 
COPD exacerbation are smoking cessation and use of focused self-care management 
techniques.  Although smoking prevention is the major focus in preventing COPD and 
smoking rates have decreased since 1954 to current day, COPD continues to rise and is 
now the third leading cause of death in the United States (CDC, 2013).   However, 
Bourbeau (2003) evaluated 10 studies that showed a correlation with improved health 
and decreased use of medical resources for COPD clients who engaged in self-
management that included relaxation strategies.  It is an anticipated outcome of this 
project that combining an awareness  of the relationship between  AATD and COPD, 
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opportunities for genetic testing, and knowledge of self-care management strategies and 
resources, such as smoking and cessation and relaxation techniques, will result in COPD 
patients taking a more focused approach to attenuating onset and exacerbation of this 
condition. 
In COPD prevention and exacerbation management, current measures focus on 
smoking cessation and prevention as the primary measure (CDC, 2013).  The CDC 
(2013) approximates 20% of smokers will experience COPD.  Statistics on other factors 
contributing to COPD such as genetic factors are unavailable except the estimated 4% 
with AATD (CDC, 2013).  Without the incidence data to connect genetic factors to 
COPD exacerbation, smoking prevention becomes the only reasonable measure for 
focus in prevention that is statistically connected to smoking.  Bridging this knowledge 
gap provides for alternate measures to decrease incidence and exacerbation of COPD 
such as targeting aggressive preventative measures to high risk families.  
Implications for Social Change in Practice   
For this project, the social change implications were related to an increased 
quality of life for the COPD client.  Disabilities in lifestyle, employment, and self-care 
present a major concern for early onset COPD clients.  Planning for exacerbation 
prevention for this population requires a holistic view that can encourage self-
management and maintain productivity.  Keeping this population productive longer can 
affect individual lives and enhance the community with capable, independent members 
as well as contributing to an overall decrease in healthcare cost and utilization.  
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Project Questions   
The questions guiding this project were the following:  
 What are the risk factors for AATD present within a geographically 
       defined COPD population?  
 What are the opinions of the target population in changing lifestyle to 
prevent COPD exacerbation?  
 How does the presence of risk factors for AATD within the COPD 
population of the Key Peninsula in Washington State compare with those 
reported by the CDC? 
 Evidence-Based Significance of the Project   
In 2003, the American Thoracic Society published a document describing 
standards for diagnosis and management of AATD.  The recommendations at that time 
included testing new COPD and asthma diagnosed clients for genetic factors (American 
Thoracic Society, 2003).  In 2005, Campos, Wanner, Zhang and Sandhaus estimated 
only 5% of AATD cases had been diagnosed up to 2003.  The CDC (2013) continues to 
estimate only 3% to 5% of COPD is related to AATD, yet testing has not become 
standard.  In 2012, Blue Cross and Blue Shield of Montana set out a standard for testing 
for AATD that includes testing for clients with clinical presentation or familial history.   
Recommendations continue to be made for testing; however, incidence rates continue to 
be only estimates. The lack of awareness of genetic factors for COPD and ability to 
obtain free AATD testing is a major barrier that can be remedied with public exposure to 
this issue.   
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In the United Kingdom, AATD is listed as an autosomal recessive genetic 
disorder with an incidence second to cystic fibrosis and is number 11 on the list of 23 
genetic disorders related to chronic disease (Genetic Alliance, 2013).  However, on the 
CDC (2013) site, although COPD is the third highest cause of hospitalization in this 
country (CDC, 2013), AATD is not mentioned nor is any other potential genetic 
connection to COPD except as a ruled out neonatal testing disorder.   Therefore, the 
need for practice change in genetic testing is evident even though the change is slow 
despite recommendations by the American Thoracic Society (2003).   
The anticipated outcomes for testing according to the American Thoracic Society 
standard for AATD can be seen on both the individual client basis and population health 
improvements (Carpenter et al., 2007).  Acknowledging genetic factors allows multiple 
interventions for self-care management that can improve individual health and future 
family health instead of focusing on only the smoking issue.  Additionally, healthcare 
facilities and the community can begin to provide environmental protection for AATD 
affected persons, including air quality and prevention of upper respiratory diseases.  In 
addition, having increased tools available for COPD prevention can decrease 
exacerbation rates and improve economic outcomes.  Maintaining quality of life and 
decreasing disability rates for this group can impact the healthcare cost.   
Recognition of genetic factors in illness and how to use these factors in ethical 
ways pose issues for both stakeholders and end-users.  Decreasing smoking rates and 
respiratory illness is part of promoting healthy living (Healthy People 2020, 2012).  
Improving knowledge and access and promoting health are key factors.  Providing 
interventions for COPD management that address genetic, environmental, and healthy 
7 
 
 
habits, rather than just a single factor etiology, can serve to promote a healthy lifestyle.  
Education for providers on testing and treatment availability can provide options for 
individual clients and population based care. 
Awareness and education programs for providers to identify at risk clients are 
necessary to have stakeholders use testing standards and target high risk individuals for 
preventative programs.  Identification of AATD prevalence within the COPD population 
is a required first step for the healthcare providers to recognize genetic factors as a valid 
risk.  
Definition of Terms   
There are multiple genetic factors that can affect the respiratory system including 
AATD, immune deficiency syndrome, and cystic fibrosis (CDC, 2013).  For the purpose 
of this project the genetic factor was AATD.  COPD, for this study, included 
emphysema, chronic bronchitis and adult onset asthma. 
   For COPD, causation can be from both internal and external factors for the 
susceptible host.  Smoking or exposure to smoke is an external contributing factor for 80 
to 90% of those with COPD (CDC, 2012).  Other external factors include environmental 
and occupational exposure, allergies, and respiratory infection (CDC, 2012).  Alpha-1 
antitrypsin is a protein that protects white blood cells from damaging normal tissue such 
as lung tissue and circulates in the blood stream.  In persons affected with the genetic 
disorder AATD, the protein is deficient or lacking causing lung tissue to become 
damaged when white cells are present in the lungs for various reasons such as bronchitis, 
pneumonia, allergies, and irritants (American Thoracic Association, 2003).  This 
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becomes an internal factor that is a genetic with a sequence of lung tissue damage in 
response to irritants or illness.  (see Appendix A). 
Assumptions and Limitations   
The assumptions underlying the project were, first, that genetics interact with the 
environment and irritants, affecting the health of an individual (Janz & Becker, 1984).  
Second is that the individual has psychosocial interactions and interpersonal 
relationships that affect decision making (Janz & Becker, 1984).  Using the health belief 
model, it is assumed that increased awareness of risk for disease can improve the 
potential for self-care management in the COPD population (Deavenport, Modeste, 
Marshak, & Neish, 2010).  It is important to understand and clarify assumptions to 
minimize researcher bias in any significant study that may include personal views of 
participants or researchers (Terry, 2012).    
 Limitations are noted in fiscal and time limitations along with procedural 
difficulties. Barriers for procedural issues include an undefined sample size and potential 
for limited response.  A significant barrier is clients not wanting to hear potential health 
risks or that the information is not useful (Bernhardt & Pyeritz, 2011).  Another factor in 
low testing rates is the lack of knowledge of availability of free testing for clients by 
both clients and providers (Berhardt & Pyeritz, 2011).  To combat this, increased 
awareness of the potential benefits must be made clear to the public with education.  
Individuals must be assured that testing is confidential and genetic discrimination must 
be legally managed.  Time-line limitations become significant with sample participation, 
as potential respondents may not return surveys in a timely manner.   
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In summary, awareness of genetic factors allows clients multiple interventions 
for healthcare management that can improve individual health and future family health 
instead of focusing on only the smoking issue.  Public facilities and communities can 
begin to provide environmental protection for AATD affected persons including air 
quality, irritant-free home heating systems, and prevention of upper respiratory diseases.  
Having increased tools available for COPD prevention can decrease exacerbation rates 
and improve economic outcomes.  Maintaining quality of life and decreasing disability 
rates for this group can impact the healthcare cost.  Targeting those individuals with high 
risk for COPD early in life can delay or prevent onset and decrease severity. 
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Section 2:  Review of Literature and Theoretical and Conceptual Framework   
Review of Scholarly Evidence 
The problem presented for this DNP project was that the COPD population may 
be unaware of AATD as an influencing factor on the exacerbation and severity of this 
disease condition, resulting in under-treatment and lack of preventive planning.  The 
purpose of the project, therefore, was to increase knowledge and awareness regarding 
the genetic factor AATD) in those patients diagnosed with COPD and to provide 
opportunities for genetic testing and information on self-care management strategies. 
An assumption of this project was that the COPD population is unaware of 
AATD as an influencing factor on the exacerbation and severity of this disease condition 
resulting in under-treatment and lack of preventive planning.  A review of the literature 
was conducted using both the Walden University Library and the worldwide web 
(www).  Google, Scholar, CINAHL, and MEDLINE/PubMed were searched for English 
language.  Key search terms included AATD, Alpha-1 Antitrypsin Deficiency, genetic 
factors, COPD, obstructive lung disease, prevalence, and self-care.  Results of the 
search were limited to current evidence-based studies.  Many prevalence studies were 
international. In the United States, however, only estimates were found for 
prevalence.  Although these research articles are important to the topic of AATD, little 
relevance was found to the main purpose of this study.  Foundational research was found 
in earlier articles from the American Thoracic Society in 2003 and has been referred to 
in research throughout the years.  Peer review articles were found in relation to COPD 
prevention but little on increasing awareness of AATD within the COPD population. 
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Specific Literature  
 Facilitators for the change to increase testing for genetic factors includes 
agencies such as the Alpha-1 Foundation (2013) which provides free testing for at risk 
individuals and families.  The barriers include lack of awareness of genetic 
predisposition and potential cost for testing along with the correlation of smoking as the 
major contributor to COPD exacerbation (CDC, 2012).   Johnson, Campbell, Bowers, 
and Nichol (2007) asserted that the COPD patient has a stigma that holds the patient 
responsible for causing their illness, which affects healthcare quality.  This is a bias that 
affects the ability of healthcare providers to look for other factors related to COPD 
etiology, regardless of whether the client ever even smoked.   
Smoking prevention is considered to be a cost effective method of controlling the 
rise of COPD (Tsevat, 1992).  Studies have been done showing a variety of genetic 
factors that contribute to the rapid COPD progression (Sanford, Weir, & Pare, 1997).  
Concentrating the efforts of smoking prevention for those at risk for rapid COPD 
progression can improve outcomes of patient lives.  Campos, et al., (2005) discussed the 
trends and barriers in diagnosis of AATD that have not improved despite 
recommendation by the American Thoracic Association to test newly diagnosed COPD 
clients (American Thoracic Association, 2003).  In 2013, Stoller and Brantly again 
discussed the challenges of diagnosis with an estimated 10% of American AATD 
patients diagnosed.  Estimates from studies such as Spinola (2009) provided information 
about multiple ethnic groups affected by AATD.  Moreover, Bourdeau (2010) compared 
the prevalence to that of cystic fibrosis rates. 
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In 2005, Lindberg, Bjerg-Backlund, Ronmark, Larsson, and Lundback conducted 
a study that documented a significant family correlation in both obstructive airway 
disease and chronic obstructive airway disease along with a greater than expected result 
for clients who have never with disease.  The research question for the awareness of risk 
for AATD within the COPD population can easily be seen as a gap in current, available 
data that requires addressing. 
Theoretical Framework 
  The health belief model provided the theoretical framework for this project. The 
health belief model originated in the U.S. Public Health Service social psychology 
department.  The focus of the model was low rates of participation in preventive health 
programs by the populations.   
The HBM centers on the client perspective of the risk for a specific disease and 
the severity of the disease (Hodges & Videto, 2011).  The likelihood of change for 
preventative action is an equation of the perceived benefits minus the perceived barriers 
for the preventative action (Nursing Theories, 2013).  Modifying factors are involved 
and include demographics, socio-psychological issues, and cues to action such as family 
illness, provider suggestion, media, or social suggestion (Hodges & Videto, 2011).  For 
the health belief model, the disease must be perceived as a significant risk factor for the 
person and have available modifying factors that the person can change.  Resources may 
need to be moved from competing areas of perceived risk for the individual to meet the 
change (see Appendix B). 
In nursing, the use of HBM is seen in health promotion.  For example, 
Deavenport et al. (2010) studied the lack of mammogram screening in low-income 
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Hispanic women.  They used questions for the study that related to HBM concepts.  The 
perceived risk for breast cancer needed to outweigh the other issues for the women in the 
population and adequate modification factors needed to be present.  Screening for breast 
cancer needed to have high enough risk to require resource use from competing risks 
present.  Janz and Becker (1984) presented a review of 29 studies using HBM with 
perceived barriers and perceived susceptibility both having strong significance for 
action.  Kaufert, Rabkin, Syrotuik, Boyoko, and Shane (1986) also showed correlation 
with general health concerns and perceived vulnerability with smoking in a health 
education program.  The application of this model for smoking cessation, breast cancer 
screening, and other preventative health programs provides a basis for use of this model 
for a program that is preventative and coupled with genetic considerations (see 
Appendix B).  For AATD management and COPD prevention, many of the health 
promotion activities are not high resource utilizers but lifestyle changes.  Understanding 
genetic components can increase the perceived risk and promote behavioral change 
without requiring high resource demands (Bourbeau, 2010). 
Program Planning for AATD Prevalence in COPD 
 Program planning for AATD prevalence within a COPD population was based 
on client perception of the disease process and factors contributing to that process.  Not 
every COPD client is going to be positive for genetic factors.  However, the process of 
beginning to look at contributing factors and potential for minimizing respiratory 
symptoms can begin with the questions about contributing factors and genetics for this 
population.  The question of what the client sees as a contributing factor to the disease 
realizes that potential.  Changes in perceived risk for disease can change potential for 
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preventative action (Hodges & Videto, 2011).  Hodges and Videto (2011) asserted that 
health education program designs that alter the client or population perception of 
susceptibility to a disease can be effective for promoting self-care and preventive care 
actions. The program for increasing knowledge of AATD within the COPD population 
was an assessment of the population views and an educational project that was 
specifically designed to alter the client, population, and healthcare provider perception 
of the risk factors and susceptibility to COPD by identifying risk of genetic factors as 
significant in the onset and exacerbation of COPD. 
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Section 3:  Methodology 
Project Design and Methods 
 This was an exploratory project using survey methods with a volunteer sample.  
This method was chosen due to the ease of participation for the sample population.  
Likert-like questions were used to gather information about risk factors and symptom 
exacerbation related to disease process (see Appendix C). 
Population and Sampling 
 The target population for this assessment is COPD patients using a specified 
local pharmacy in Washington State.  Convenience sampling was used. The sample 
population was a voluntary group of clients from among the 250 to 300 clients renewing 
COPD medications of inhalers in the specific local pharmacy. Although AATD rates are 
estimated at 4% of the COPD population in the United States (CDC, 2013), European 
studies show rates as high as 1 in 25 in entire populations (Campos, et al., 2005).  In 
Kitsap County, Washington State, the project site shows European heritage up to 28% 
(USA.com, 2013), making this a potential ''hot spot'' of COPD influenced by AATD. 
Assessing this population for demographics, care management strategies, and 
history along with providing testing information for AATD testing in the survey can 
guide the change in preventative programs for COPD.  The COPD patients from the 
pharmacy can voluntarily return the survey and make their own appointments for testing 
for AATD.  Risk factors for AATD may be identified from survey results.  This sample 
population would be generalizable to the area to design preventative programs for 
COPD and smoking cessation. 
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Recruitment and Distribution of the Survey 
  The COPD survey was brought to the pharmacy where pharmacy clients refill 
medication for COPD and asthma on a routine basis monthly.  The pharmacist offered 
the survey to the client at the medication refill time and described participation.   
    Data were collected using survey methods. The surveys were distributed and 
collected over a month’s time.  Data were collected using survey methods. The survey 
included demographic data using descriptor choices and disease history as well as needs 
assessment information using Likert-like questions. The survey was completed by the 
participant and returned to me via the self-addressed stamped envelope provided. The 
needs assessment for this population specifically focused on the value the population 
places on a variety of contributing factors and willingness to participate in prevention 
interventions for those factors including smoking, environment, respiratory infections, 
and genetics (see Appendix D). 
 
    Protection of Human Subjects 
  Informed consent was provided to each respondent, and voluntary participation 
information was included with the survey brochure. The regulations of Walden 
University in the conduct of human subject protection were followed throughout the 
conduct of this project. Anonymity of the respondents was maintained. No names or 
other personal identification were solicited. The IRB representative was identified for 
clients and the number for access was included (612-312-1210). Completed surveys 
were kept in a locked file drawer in my office for a period determined by the Walden 
University IRB. 
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Data Analysis   
Demographic data were calculated for percentages.  Likert-like survey questions 
have mean results for willingness to change and ATTD knowledge.  Central tendency 
data for risk factors was performed as appropriate to data.  Data analysis was done for 
the quantitative data to compare risk rates for AATD in the sample population to the 
estimated AATD rates presented by the CDC. Correlation was done using the onset age 
and number of family members with symptoms. 
Summary 
  A project that focuses on identifying high risk for AATD within a COPD 
population can provide increased resources for decreasing the COPD onset and 
exacerbation rates.  The results of the project needed to be disseminated in order to 
promote the use of increased resources and to promote holistic preventative plans for 
preventing COPD onset and exacerbation. Dissemination of information must include 
the target population and the health care policy makers and providers (Hampton, 2011b).  
The target population had the opportunity to be informed of project results and resources 
at a post conference for participants that was open to the community following data 
analysis.  Information about the project may have direct effects on the quality of life for 
the participants and community.  The project poster was submitted to Sigma Theta Tau 
(see Appendix E) and research brief manuscript to the CDC Chronic Disease Prevention.  
Reaching the nursing professionals with data to address genetic factors in health 
prevention issues would provide options for health care planning in COPD and other 
chronic diseases.  An additional presentation was to be made to the partnering agency 
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stakeholders.  The purpose was for planning healthcare resource management and 
marketing for the COPD population in the community.   
Result dissemination was viewed with ethical considerations.  Confidentiality 
and anonymity were maintained for the participants in result reporting.  Ethical practice, 
also, dictates that the participants have an opportunity to receive follow-up care for 
potential stress or physical results from the study.  Resources were provided for follow-
up in the post conference.  Regardless of study results, the potential for quality of life 
improvements with self-care education and follow-up can provide continued progress 
toward meeting the goals of Healthy People 2020. 
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Section 4:  Findings, Discussion, and Implications 
Summary of Findings 
 Participation rates for the survey were calculated on the responses to the 
invitation to participate. Each variable in the survey was calculated for distribution, 
central tendency, and dispersion. All invited clients received the educational and survey 
materials. Data were not available on whether the clients reviewed the materials.  There 
were 33 respondents to the survey.  Two respondents were disqualified related to age 
outside of survey criteria; therefore, the sample size for this study was 31 participants 
who met the 95% confidence interval for non-medical research, and was large enough to 
meet the tenets of the central limits theorem regarding a normal distribution of the 
sample (Dinov, Christou, & Sanchez, 2008).  
Gender of the sample was split equally within the respondents with one 
respondent not answering the gender question.  Of the 31 respondents eligible for 
participation, the majority were aged 41 to 60 years (48.3%), followed the 61 to 65 years 
(45.2%).  Female respondents were younger than male respondents (see Appendix D). 
The participants reported onset of symptoms earlier than 40 years in 45.2% of responses. 
Onset of symptoms between 41 and 60 was reported by 38.7%. Symptom onset between 
61 to 65 years was reported by only 16% of the respondents.  Symptom onset for 60 
years and less was 84%.  Only 22.6% of the respondents reported no other family 
members with symptoms. Smoking made symptoms worse for 80.6% of the respondents 
while 48.3% found other irritants to exacerbate symptom. These include respiratory 
infection (45.2%), allergies (48.3%), and pollution (29%). 
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   The survey asked the participants to report what made their symptoms improve. 
Medication improved 93.5% of the respondents. Only 13% of respondents reported that 
clean air improved symptoms. One respondent reported that nothing improved 
symptoms. Smoking cessation improved 58% of the participants’ symptoms. Of the 
respondents with onset at 60 years and earlier and a family history, 52.2% reported no 
improvement in symptoms with smoking cessation. This group comprised 38.7% of all 
respondents to the survey. The survey showed close to 68% of the respondents wished to 
know if they had a genetic predisposition for COPD with 55% willing to change 
behaviors if they knew about a genetic predisposition. 
Correlation was conducted using Pearson’s r value for age of onset as the 
independent value and family history as the dependent value. Calculations were done by 
assigning Likert values to the variables. The female respondent r value of 0.3384 
showed a moderately positive correlation (p = 0.2173) but was not statistically 
significant.  The male respondent value of r = .6488 showed a high positive correlation 
and statistical significance within the variables (p = 0.0089). The entire respondent value 
of r = 0.5272 represents a moderate positive correlation that is statistically significant 
between early onset symptoms and family history (p = 0.0023). 
  Discussion and Implications 
 The implications were based around the trends noted in the responses of the 
returned surveys.  Positive correlation between early onset symptoms and positive 
family history of COPD suggests a higher percentage of genetic involvement than the 
4% estimated by the CDC, 2013.  In this small convenience sample, the percentage of 
those with COPD and family history was 77.4%.  Rates for actual risk for genetic 
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involvement were not found in the CDC statistics for U.S. populations.  Testing for 
genetic factors as recommended by the American Thoracic Society (2003) may prove 
helpful in minimizing COPD frequency and severity.  Positive and significant 
correlation of early onset symptoms and positive family history, as found in this project, 
can provide the opportunity to target high risk families for preventative programs that 
can begin early in life and focus on promotion of respiratory health, including 
pulmonary toilet, and prevention of high risk habits. 
Genetic diseases affect an estimated 12 million Americans, yet according to a 
survey of 1,000 people conducted by the Genetic Disease Foundation , while two-thirds 
of those surveyed were willing to and saw the benefits of undergoing testing, close to 80 
% had never talked to their physician about genetic screening–an inconsistency that can 
have serious implications on a person’s overall health and the health of their immediate 
family members. Given the results of this project, that 45% of respondents met the 
criteria for genetic testing for COPD, it is important to realize that in fact, almost every 
human trait and disease has a genetic component, and there are more than 6,000 known 
genetic disorders, from widely recognized conditions like Down syndrome, spina-bifida 
and sickle cell anemia, to lesser-known conditions like Tay-Sachs disease and Fabry 
disease (Genetic Alliance. 2013).  
Genetic diseases are caused by abnormalities in a person's DNA and can range 
from a small mutation in a single gene to the addition or subtraction of an entire 
chromosome or set of chromosomes. These abnormalities can disrupt the normal 
function of a vital system, such as the immune system or the nervous system, or prevent 
normal development of organs, bones, or skin, significantly increasing a person’s chance 
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of developing a particular disease. The addition of both environmental and lifestyle 
factors to the genetic abnormalities has a significant impact on the development of 
disease in specific groups of individuals. 
 The results of the study support the use of the health belief model for improving 
outcomes in patients with COPD and risk factors for AATD.  This is evident by the 
survey results of willingness to change health behaviors with knowledge of genetic risk.  
The knowledge of risk for AATD can provide an increased perceived risk for the COPD 
client and other family members.  The model supports that the perceived risk for disease 
improves the potential for participation in healthy behaviors.  The survey results indicate 
that using the health belief model to develop COPD prevention and management 
programs, especially for those at risk for AATD, would be successful. 
 This project provided a survey that supports the results of studies that have done 
AATD testing such as Spinola (2009) and Bourbeau (2010).  Although it did not provide 
actual AATD incidence rates, the study provided information that there is a higher 
population at risk for AAT with COPD than the CDC (2013) rates indicated.  The 
expanded knowledge of risk for early COPD onset and exacerbation related to family 
members with COPD is knowledge that is useful to program development and target 
populations. 
 
Strengths and Limitations 
The primary focus of the project was to increase knowledge for AATD risk 
within the sample population. All of the sample population received information about 
prevention for exacerbation of COPD and risk for genetic predisposition. It was 
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undeterminable whether the sample population read the supplied material. However, the 
information was made accessible to this population. 
  The next limitation for this project was found in the response rate to the survey 
of COPD clients at the local pharmacy who were invited to participate. In the 6-week 
period, only 35 of the 75 surveys were distributed to clients. Self-reporting can have 
limited reliability in surveys (Terry, 2012). Therefore, in order to promote accurate 
answers, smoking status was not asked in the survey. Trends were visible in the 
responses of the participants.  The survey collection occurred from March 01, 2015 to 
April 10, 2015.  Two additional responses were received but ineligible to age.  
Although the survey responses did not provide information for specifically 
AATD, it provided information that suggests familial or genetic factors in the 
respondents. More than 70% of respondents had indicators of both early onset and 
positive family history that would qualify for AATD testing.  Further testing would be 
required to determine the nature of the trends.  These could be related to genetic factors, 
familial life style factors, or environmental factors.  
   The survey information provides a basis for further research on the prevalence of 
genetic predisposition for COPD. The responses of the participants also provided data 
that supports that this knowledge may improve the quality of life for this population by 
targeting health prevention programs to those families at risk for COPD. Johnson et al. 
(2007) asserted that there is a stigma of patient blame that affects healthcare of this 
population, and Berger, Kapella, and Larson (2011) attributed this increasing trend of 
patient blame for COPD to smoking. Dispelling the blame for COPD from the patients 
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may improve healthcare responsiveness along with social interaction and self-care 
management. 
Evaluation and Analysis of Self 
  As a practitioner in healthcare, the DNP process has increased my own need to 
improve assessment skills of individuals and populations.  This was especially important 
to me as the Affordable Care Act (2010) promotes universal health insurance coverage 
and population health to improve health equity and outcomes.  There is a trend to move 
away from illness focused care toward population health and preventative healthcare 
services.  The ability to provide evidence-based care requires a deeper level of 
assessment in order to provide care that truly minimizes and prevents illness.  Care that 
stems from limited assessment and unfounded practices can no longer provide what is 
required to improve the national health dilemma.  As a scholar, it has become important 
to me to provide research and evidence-based studies that can improve individual and 
population based outcomes.  The work is not easy, but having completed a DNP 
education, this work is manageable.  For nursing to survive the healthcare system as it 
evolves, evidence-based knowledge must be part of the professional obligations.  The 
leadership role of the DNP can provide this knowledge and move nursing forward as a 
recognized profession.  For me, having close to 40 years of practice as a nurse, it is 
important to provide future nurses with the knowledge and skills that can continue to 
provide improved outcomes and quality of life for the individual as well as the 
community.  I have seen how this specific project working with the COPD population 
has the potential to improve quality of life at multiple levels. 
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Summary and Conclusions 
    The project for increasing knowledge for AATD within the COPD population 
accomplished two objectives.  First, it provided information about the potential 
relationship between genetic factors and COPD, which could result in the prevention of 
exacerbation for COPD clients.  Secondly, it provided information on the risk factors for 
AADT found in the sample population.  The results of the survey in this project indicate 
familial trends for COPD clients consistent with AATD testing qualifications, but did 
not provide specific genetic indicators.  The results support that testing for 
predisposition to COPD is a factor that could decrease the frequency and severity of 
COPD exacerbation.  The continuing increasing national burden of COPD demands that 
healthcare providers do more for the at risk population than provide advice for smoking 
cessation.  Positive health promotion, including genetic testing and lifestyle support, 
could begin to decrease the individual and national cost of this disabling disease. 
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Section 5:  Scholarly Product 
A research brief was written for submission for publication with the CDC 
Chronic Disease Prevention.  This was done with the assistance of Dr. Cheryl Holly as 
coauthor. 
A poster was also constructed that will be on display at the local pharmacy for 
the community to view.  This is being done to improve the awareness of AATD and 
COPD prevention.  The poster will be on view where the participants of the survey may 
view it. 
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Appendix A: COPD Web of Causation 
COPD Web of Causation 
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Appendix B:  Alpha-1 Antitrypsin Deficiency within COPD Using Health 
Belief Model 
 
Individual Perceptions                       Modifying Factors  Likelihood of 
Change Action 
 
Perceived Susceptibility  Demographics (Environment) 
To disease   Socio-psychological  
(Personal habits, genetics)   Structural variables   
Perceived 
benefits 
minus  
          Perceived 
barriers 
Perceived Severity  
 Of disease 
(Decreased life quality, death)  Perceived threat of disease 
 
     Cues to Action 
   Raised awareness (AATD diagnosis, genetic awareness) 
   Personal advice (patient education) 
   Personal symptoms or illness of family or friend    (history) 
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Appendix C:  Tools 
Prevalence of Alpha-1 Antitrypsin Deficiency (AATD) within the 
COPD Population of Key Peninsula (Genetic Predisposition) Survey 
Part 1 Demographics:   (Please circle your answer) 
1.  What is your sex?    a. Male     b. Female 
2. What is your age?    a.18-40    b.  41-60   c.  61-65 
3. At what age did your symptoms begin? a.18-40   b. 41-60 c. 61-65 d. Other__ 
4. How many members of your family also have symptoms of COPD?  a. 0   b. 1-3   
c. 4 or more 
Part 2 Contributing Factors:  (Please circle all that apply) 
1. What makes your symptoms worsen? 
a. Respiratory infections          b.  Allergies     c.  Pollution     d.  Smoke   
 e. Other_____ 
 
2. What makes your symptoms improve? 
a.  Medication    b.  Clean air   c.  Smoking cessation   d.  Relaxation   e.  none     
f.    Other_______ 
 3.  Would you want to know if you had genetic predisposition to COPD?   
a. Yes b. No    
4.    Would awareness of predisposing genetic factors for COPD change your 
Life style? a. Yes                   b.   No 
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Appendix D: Figures 
 
 
 
 
 
Figure 1. Age symptoms started 
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Figure 2. Number of family members with COPD 
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Figure 3.  What makes symptoms worse? 
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Figure 4.  What makes symptoms improve? 
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Figure 5.  Genetic pre-disposition and willingness to change lifestyle 
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Figure 6.  Age of participants 
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Figure 7. Positive correlation for early onset symptoms with increased number of family 
with symptoms (n = 31, r = 0.5272, p = 0.0023). 
 
